Insulin - Related Links
Open Access Articles- Top Results for Insulin
Clinical Pharmacology & BiopharmaceuticsProblems of using Hydrochlorothiazide Diuretic in Adult Diabeti c Patient in Diabetic Clinic of Adama Hospital Medical College, E ast Shoa Zone, Oromi
Enzyme EngineeringImpaired Glucose Metabolism in Alzheimers Disease and Diabetes
Journal of Metabolic SyndromePull the Trigger, it Fires: The Critical Role of Insulin-Stimulated Caveolin-1 Tyrosine 14 Phosphorylation in Regulation of Insulin Trans-Endothelial
International Journal of Advanced Research in Electrical, Electronics and Instrumentation EnergyNon-Invasive Patient Health and Insulin Level Monitoring System
International Journal of Advanced Research in Electrical, Electronics and Instrumentation EnergyLabView Based Glucose Insulin Regulation Using System Identification Approach
|Symbols||; IDDM1; IDDM2; ILPR; IRDN; MODY10|
|External IDs||ChEMBL: GeneCards:|
|RNA expression pattern|
|File:PBB GE INS 206598 at tn.png|
Insulin (from the Latin, insula meaning island) is a peptide hormone produced by beta cells in the pancreas. It regulates the metabolism of carbohydrates and fats by promoting the absorption of glucose from the blood to skeletal muscles and fat tissue and by causing fat to be stored rather than used for energy. Insulin also inhibits the production of glucose by the liver.
Except in the presence of the metabolic disorder diabetes mellitus and metabolic syndrome, insulin is provided within the body in a constant proportion to remove excess glucose from the blood, which otherwise would be toxic. When blood glucose levels fall below a certain level, the body begins to use stored glucose as an energy source through glycogenolysis, which breaks down the glycogen stored in the liver and muscles into glucose, which can then be utilized as an energy source. As a central metabolic control mechanism, its status is also used as a control signal to other body systems (such as amino acid uptake by body cells). In addition, it has several other anabolic effects throughout the body.
When control of insulin levels fails, diabetes mellitus can result. As a consequence, insulin is used medically to treat some forms of diabetes mellitus. Patients with type 1 diabetes depend on external insulin (most commonly injected subcutaneously) for their survival because the hormone is no longer produced internally. Patients with type 2 diabetes are often insulin resistant and, because of such resistance, may suffer from a "relative" insulin deficiency. Some patients with type 2 diabetes may eventually require insulin if dietary modifications or other medications fail to control blood glucose levels adequately. Over 40% of those with Type 2 diabetes require insulin as part of their diabetes management plan.
Insulin is a very old protein that may have originated more than a billion years ago. The molecular origins of insulin go at least as far back as the simplest unicellular eukaryotes. Apart from animals, insulin-like proteins are also known to exist in Fungi and Protista kingdoms. The human insulin protein is composed of 51 amino acids, and has a molecular weight of 5808 Da. It is a dimer of an A-chain and a B-chain, which are linked together by disulfide bonds. Insulin's structure varies slightly between species of animals. Insulin from animal sources differs somewhat in "strength" (in carbohydrate metabolism control effects) from that in humans because of those variations. Porcine insulin is especially close to the human version.
- 1 Gene
- 2 Protein structure
- 3 Synthesis, physiological effects, and degradation
- 4 Hypoglycemia
- 5 Diseases and syndromes
- 6 Medication uses
- 7 Zoology
- 8 History
- 9 See also
- 10 References
- 11 Further reading
- 12 External links
Several regulatory sequences in the promoter region of the human insulin gene bind to transcription factors. In general, the A-boxes bind to Pdx1 factors, E-boxes bind to NeuroD, C-boxes bind to MafA, and cAMP response elements to CREB. There are also silencers that inhibit transcription.
|Regulatory sequence||binding transcription factors|
|negative regulatory element (NRE)||glucocorticoid receptor, Oct1|
|Z (overlapping NRE and C2)||ISF|
|CREB RE||CREB, CREM|
|CAAT enhancer binding (CEB) (partly overlapping A2 and C1)||-|
|E1||E2A, NeuroD1, HEB|
Within vertebrates, the amino acid sequence of insulin is strongly conserved. Bovine insulin differs from human in only three amino acid residues, and porcine insulin in one. Even insulin from some species of fish is similar enough to human to be clinically effective in humans. Insulin in some invertebrates is quite similar in sequence to human insulin, and has similar physiological effects. The strong homology seen in the insulin sequence of diverse species suggests that it has been conserved across much of animal evolutionary history. The C-peptide of proinsulin (discussed later), however, differs much more among species; it is also a hormone, but a secondary one.
The primary structure of bovine insulin was first determined by Frederick Sanger in 1951. After that, this polypeptide was synthesized independently by several groups. The 3-dimensional structure of insulin was determined by X-ray crystallography in Dorothy Hodgkin's laboratory in 1969 (PDB file 1ins).
Insulin is produced and stored in the body as a hexamer (a unit of six insulin molecules), while the active form is the monomer. The hexamer is an inactive form with long-term stability, which serves as a way to keep the highly reactive insulin protected, yet readily available. The hexamer-monomer conversion is one of the central aspects of insulin formulations for injection. The hexamer is far more stable than the monomer, which is desirable for practical reasons; however, the monomer is a much faster-reacting drug because diffusion rate is inversely related to particle size. A fast-reacting drug means insulin injections do not have to precede mealtimes by hours, which in turn gives people with diabetes more flexibility in their daily schedules. Insulin can aggregate and form fibrillar interdigitated beta-sheets. This can cause injection amyloidosis, and prevents the storage of insulin for long periods.
Synthesis, physiological effects, and degradation
Insulin is produced in the pancreas and released when any of several stimuli are detected. These stimuli include ingested protein and glucose in the blood produced from digested food. Carbohydrates can be polymers of simple sugars or the simple sugars themselves. If the carbohydrates include glucose, then that glucose will be absorbed into the bloodstream and blood glucose level will begin to rise. In target cells, insulin initiates a signal transduction, which has the effect of increasing glucose uptake and storage. Finally, insulin is degraded, terminating the response.
In mammals, insulin is synthesized in the pancreas within the β-cells of the islets of Langerhans. One million to three million islets of Langerhans (pancreatic islets) form the endocrine part of the pancreas, which is primarily an exocrine gland. The endocrine portion accounts for only 2% of the total mass of the pancreas. Within the islets of Langerhans, beta cells constitute 65–80% of all the cells.
Insulin consists of two polypeptide chains, the A- and B- chains, linked together by disulfide bonds. It is however first synthesized as a single polypeptide called preproinsulin in pancreatic β-cells. Preproinsulin contains a 24-residue signal peptide which directs the nascent polypeptide chain to the rough endoplasmic reticulum (RER). The signal peptide is cleaved as the polypeptide is translocated into lumen of the RER, forming proinsulin. In the RER the proinsulin folds into the correct conformation and 3 disulfide bonds are formed. About 5–10 min after its assembly in the endoplasmic reticulum, proinsulin is transported to the trans-Golgi network (TGN) where immature granules are formed. Transport to the TGN may take about 30 min.
Proinsulin undergoes maturation into active insulin through the action of cellular endopeptidases known as prohormone convertases (PC1 and PC2), as well as the exoprotease carboxypeptidase E. The endopeptidases cleave at 2 positions, releasing a fragment called the C-peptide, and leaving 2 peptide chains, the B- and A- chains, linked by 2 disulfide bonds. The cleavage sites are each located after a pair of basic residues (lysine-64 and arginine-65, and arginine-31 and -32). After cleavage of the C-peptide, these 2 pairs of basic residues are removed by the carboxypeptidase. The C-peptide is the central portion of proinsulin, and the primary sequence of proinsulin goes in the order "B-C-A" (the B and A chains were identified on the basis of mass and the C-peptide was discovered later).
The resulting mature insulin is packaged inside mature granules waiting for metabolic signals (such as leucine, arginine, glucose and mannose) and vagal nerve stimulation to be exocytosed from the cell into the circulation.
The endogenous production of insulin is regulated in several steps along the synthesis pathway:
- At transcription from the insulin gene
- In mRNA stability
- At the mRNA translation
- In the posttranslational modifications
Beta cells in the islets of Langerhans release insulin in two phases. The first phase release is rapidly triggered in response to increased blood glucose levels. The second phase is a sustained, slow release of newly formed vesicles triggered independently of sugar. The description of first phase release is as follows:
- Glucose enters the β-cells through the glucose transporters, GLUT2.
- Glucose goes into glycolysis and the Krebs cycle, where multiple, high-energy ATP molecules are produced by oxidation, leading to a rise in the ATP:ADP ratio within the cell.
- An increased intracellular ATP:ADP ratio closes the ATP-sensitive SUR1/Kir6.2 potassium channel (see sulfonylurea receptor). This prevents potassium ions (K+) from leaving the cell by facilitated diffusion, leading to a buildup of potassium ions. As a result, the inside of the cell becomes more positive with respect to the outside, leading to the depolarisation of the cell surface membrane.
- On depolarisation, voltage-gated calcium ion (Ca2+) channels open which allows calcium ions to move into the cells by facilitated diffusion.
- An increased intracellular calcium ion concentration causes the activation of phospholipase C, which cleaves the membrane phospholipid phosphatidyl inositol 4,5-bisphosphate into inositol 1,4,5-trisphosphate and diacylglycerol.
- Inositol 1,4,5-trisphosphate (IP3) binds to receptor proteins in the plasma membrane of the endoplasmic reticulum (ER). This allows the release of Ca2+ ions from the ER via IP3-gated channels, and further raises the intracellular concentration of calcium ions.
- Significantly increased amounts of calcium ions in the cells causes the release of previously synthesized insulin, which has been stored in secretory vesicles.
This is the primary mechanism for release of insulin. Other substances known to stimulate insulin release include the amino acids arginine and leucine, parasympathetic release of acetylcholine (via phospholipase C), sulfonylurea, cholecystokinin (CCK, via phospholipase C), and the gastrointestinally derived incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP).
Release of insulin is strongly inhibited by the stress hormone norepinephrine (noradrenaline), which leads to increased blood glucose levels during stress. It appears that release of catecholamines by the sympathetic nervous system has conflicting influences on insulin release by beta cells, because insulin release is inhibited by α2-adrenergic receptors and stimulated by β2-adrenergic receptors. The net effect of norepinephrine from sympathetic nerves and epinephrine from adrenal glands on insulin release is inhibition due to dominance of the α-adrenergic receptors.
When the glucose level comes down to the usual physiologic value, insulin release from the β-cells slows or stops. If blood glucose levels drop lower than this, especially to dangerously low levels, release of hyperglycemic hormones (most prominently glucagon from islet of Langerhans alpha cells) forces release of glucose into the blood from cellular stores, primarily liver cell stores of glycogen. By increasing blood glucose, the hyperglycemic hormones prevent or correct life-threatening hypoglycemia.
Evidence of impaired first-phase insulin release can be seen in the glucose tolerance test, demonstrated by a substantially elevated blood glucose level at 30 minutes, a marked drop by 60 minutes, and a steady climb back to baseline levels over the following hourly time points.
Even during the digestion, in general, one or two hours following a meal, insulin release from the pancreas is not continuous, but oscillates with a period of 3–6 minutes, changing from generating a blood insulin concentration more than about 800 pmol/l to less than 100 pmol/l. This is thought to avoid downregulation of insulin receptors in target cells, and to assist the liver in extracting insulin from the blood. This oscillation is important to consider when administering insulin-stimulating medication, since it is the oscillating blood concentration of insulin release, which should, ideally, be achieved, not a constant high concentration. This may be achieved by delivering insulin rhythmically to the portal vein or by islet cell transplantation to the liver. It is hoped that future insulin pumps will address this characteristic. (See also Pulsatile Insulin.)
The blood content of insulin can be measured in international units, such as µIU/mL or in molar concentration, such as pmol/L, where 1 µIU/mL equals 6.945 pmol/L. A typical blood level between meals is 8–11 μIU/mL (57–79 pmol/L).
Special transporter proteins in cell membranes allow glucose from the blood to enter a cell. These transporters are, indirectly, under blood insulin's control in certain body cell types (e.g., muscle cells). Low levels of circulating insulin, or its absence, will prevent glucose from entering those cells (e.g., in type 1 diabetes). More commonly, however, there is a decrease in the sensitivity of cells to insulin (e.g., the reduced insulin sensitivity characteristic of type 2 diabetes), resulting in decreased glucose absorption. In either case, there is 'cell starvation' and weight loss, sometimes extreme. In a few cases, there is a defect in the release of insulin from the pancreas. Either way, the effect is the same: elevated blood glucose levels.
Activation of insulin receptors leads to internal cellular mechanisms that directly affect glucose uptake by regulating the number and operation of protein molecules in the cell membrane that transport glucose into the cell. The genes that specify the proteins that make up the insulin receptor in cell membranes have been identified, and the structures of the interior, transmembrane section, and the extra-membrane section of receptor have been solved.
Two types of tissues are most strongly influenced by insulin, as far as the stimulation of glucose uptake is concerned: muscle cells (myocytes) and fat cells (adipocytes). The former are important because of their central role in movement, breathing, circulation, etc., and the latter because they accumulate excess food energy against future needs. Together, they account for about two-thirds of all cells in a typical human body.
Insulin binds to the extracellular portion of the alpha subunits of the insulin receptor. This, in turn, causes a conformational change in the insulin receptor that activates the kinase domain residing on the intracellular portion of the beta subunits. The activated kinase domain autophosphorylates tyrosine residues on the C-terminus of the receptor as well as tyrosine residues in the IRS-1 protein.
- phosphorylated IRS-1, in turn, binds to and activates phosphoinositol 3 kinase (PI3K)
- PI3K catalyzes the reaction PIP2 + ATP → PIP3 + ADP
- PIP3 activates protein kinase B (PKB)
- PKB phosphorylates glycogen synthase kinase (GSK) and thereby inactivates GSK
- GSK can no longer phosphorylate glycogen synthase (GS)
- unphosphorylated GS makes more glycogen
- PKB also facilitates vesicle fusion, resulting in an increase in GLUT4 transporters in the plasma membrane
After the signal has been produced, termination of signaling is then needed. As mentioned below in the section on degradation, endocytosis and degradation of the receptor bound to insulin is a main mechanism to end signaling. In addition, signaling can be terminated by dephosphorylation of the tyrosine residues by tyrosine phosphatases. Serine/Threonine kinases are also known to reduce the activity of insulin. Finally, with insulin action being associated with the number of receptors on the plasma membrane, a decrease in the amount of receptors also leads to termination of insulin signaling.
The actions of insulin on the global human metabolism level include:
- Control of cellular intake of certain substances, most prominently glucose in muscle and adipose tissue (about two-thirds of body cells)
- Increase of DNA replication and protein synthesis via control of amino acid uptake
- Modification of the activity of numerous enzymes.
The actions of insulin (indirect and direct) on cells include:
- Increased glycogen synthesis – insulin forces storage of glucose in liver (and muscle) cells in the form of glycogen; lowered levels of insulin cause liver cells to convert glycogen to glucose and excrete it into the blood. This is the clinical action of insulin, which is directly useful in reducing high blood glucose levels as in diabetes.
- Increased lipid synthesis – insulin forces fat cells to take in blood lipids, which are converted to triglycerides; lack of insulin causes the reverse.[clarification needed (see talk)]
- Increased esterification of fatty acids – forces adipose tissue to make fats (i.e., triglycerides) from fatty acid esters; lack of insulin causes the reverse.
- Decreased proteolysis – decreasing the breakdown of protein
- Decreased lipolysis – forces reduction in conversion of fat cell lipid stores into blood fatty acids; lack of insulin causes the reverse.
- Decreased gluconeogenesis – decreases production of glucose from nonsugar substrates, primarily in the liver (the vast majority of endogenous insulin arriving at the liver never leaves the liver); lack of insulin causes glucose production from assorted substrates in the liver and elsewhere.
- Decreased autophagy - decreased level of degradation of damaged organelles. Postprandial levels inhibit autophagy completely.
- Increased amino acid uptake – forces cells to absorb circulating amino acids; lack of insulin inhibits absorption.
- Increased potassium uptake – forces cells to absorb serum potassium; lack of insulin inhibits absorption. Insulin's increase in cellular potassium uptake lowers potassium levels in blood. This possibly occurs via insulin-induced translocation of the Na+/K+-ATPase to the surface of skeletal muscle cells.
- Arterial muscle tone – forces arterial wall muscle to relax, increasing blood flow, especially in microarteries; lack of insulin reduces flow by allowing these muscles to contract.
- Increase in the secretion of hydrochloric acid by parietal cells in the stomach
- Decreased renal sodium excretion.
Insulin also influences other body functions, such as vascular compliance and cognition. Once insulin enters the human brain, it enhances learning and memory and benefits verbal memory in particular. Enhancing brain insulin signaling by means of intranasal insulin administration also enhances the acute thermoregulatory and glucoregulatory response to food intake, suggesting that central nervous insulin contributes to the control of whole-body energy homeostasis in humans. Insulin also has stimulatory effects on gonadotropin-releasing hormone from the hypothalamus, thus favoring fertility.
Once an insulin molecule has docked onto the receptor and effected its action, it may be released back into the extracellular environment, or it may be degraded by the cell. The two primary sites for insulin clearance are the liver and the kidney. The liver clears most insulin during first-pass transit, whereas the kidney clears most of the insulin in systemic circulation. Degradation normally involves endocytosis of the insulin-receptor complex, followed by the action of insulin-degrading enzyme. An insulin molecule produced endogenously by the pancreatic beta cells is estimated to be degraded within about one hour after its initial release into circulation (insulin half-life ~ 4–6 minutes).
Although other cells can use other fuels (most prominently fatty acids), neurons depend on glucose as a source of energy in the nonstarving human. They do not require insulin to absorb glucose, unlike muscle and adipose tissue, and they have very small internal stores of glycogen. Glycogen stored in liver cells (unlike glycogen stored in muscle cells) can be converted to glucose, and released into the blood, when glucose from digestion is low or absent, and the glycerol backbone in triglycerides can also be used to produce blood glucose.
Sufficient lack of glucose and scarcity of these sources of glucose can dramatically make itself manifest in the impaired functioning of the central nervous system: dizziness, speech problems, and even loss of consciousness. Low blood glucose level is known as hypoglycemia or, in cases producing unconsciousness, "hypoglycemic coma" (sometimes termed "insulin shock" from the most common causative agent). Endogenous causes of insulin excess (such as an insulinoma) are very rare, and the overwhelming majority of insulin excess-induced hypoglycemia cases are iatrogenic and usually accidental. A few cases of murder, attempted murder, or suicide using insulin overdoses have been reported, but most insulin shocks appear to be due to errors in dosage of insulin (e.g., 20 units instead of 2) or other unanticipated factors (did not eat as much as anticipated, or exercised more than expected, or unpredicted kinetics of the subcutaneously injected insulin itself).
Possible causes of hypoglycemia include:
- External insulin (usually injected subcutaneously)
- Oral hypoglycemic agents (e.g., any of the sulfonylureas, or similar drugs, which increase insulin release from β-cells in response to a particular blood glucose level)
- Ingestion of low-carbohydrate sugar substitutes in people without diabetes or with type 2 diabetes. Animal studies show these can trigger insulin release, albeit in much smaller quantities than sugar, according to a report in Discover magazine, August 2004, p 18. (This can never be a cause of hypoglycemia in patients with mature type 1 diabetes, since there is no endogenous insulin production to stimulate. It can occur during the honeymoon period, a period up to several years after a type 1 diabetes diagnosis during which endogenous insulin production still occurs.)
Diseases and syndromes
There are several conditions in which insulin disturbance is pathologic:
- Diabetes mellitus – general term referring to all states characterized by hyperglycemia
- Type 1 – autoimmune-mediated destruction of insulin-producing β-cells in the pancreas, resulting in absolute insulin deficiency
- Type 2 – multifactoral syndrome with combined influence of genetic susceptibility and influence of environmental factors, the best known being obesity, age, and physical inactivity, resulting in insulin resistance in cells requiring insulin for glucose absorption.
- Other types of impaired glucose tolerance (see the Diabetes)
- Insulinoma - a tumor of pancreatic β-cells producing excess insulin or reactive hypoglycemia.
- Metabolic syndrome – a poorly understood condition first called Syndrome X by Gerald Reaven. It is currently not clear whether the syndrome has a single, treatable cause, or is the result of body changes leading to type 2 diabetes. It is characterized by elevated blood pressure, dyslipidemia (disturbances in blood cholesterol forms and other blood lipids), and increased waist circumference (at least in populations in much of the developed world). The basic underlying cause may be the insulin resistance that precedes type 2 diabetes, which is a diminished capacity for insulin response in some tissues (e.g., muscle, fat). It is common for morbidities such as essential hypertension, obesity, type 2 diabetes, and cardiovascular disease (CVD) to develop.
- Polycystic ovary syndrome – a complex syndrome in women in the reproductive years where anovulation and androgen excess are commonly displayed as hirsutism. In many cases of PCOS, insulin resistance is present.
Biosynthetic human insulin (insulin human rDNA, INN) for clinical use is manufactured by recombinant DNA technology. Biosynthetic human insulin has increased purity when compared with extractive animal insulin, enhanced purity reducing antibody formation. Researchers have succeeded in introducing the gene for human insulin into plants as another method of producing insulin ("biopharming") in safflower. This technique is anticipated to reduce production costs.
Several analogs of human insulin are available. These insulin analogs are closely related to the human insulin structure, and were developed for specific aspects of glycemic control in terms of fast action (prandial insulins) and long action (basal insulins). The first biosynthetic insulin analog was developed for clinical use at mealtime (prandial insulin), Humalog (insulin lispro), it is more rapidly absorbed after subcutaneous injection than regular insulin, with an effect 15 minutes after injection. Other rapid-acting analogues are NovoRapid and Apidra, with similar profiles. All are rapidly absorbed due to sequence that will reduce formation of dimers and hexamers (monomeric insulins are more rapidly absorbed). Fast acting insulins do not require the injection-to-meal interval previously recommended for human insulin and animal insulins. The other type is long acting insulin; the first of these was Lantus (insulin glargine). These have a steady effect for an extended period from 18 to 24 hours. Likewise, another protracted insulin analogue (Levemir) is based on a fatty acid acylation approach. A myristyric acid molecule is attached to this analogue, which in turn associates the insulin molecule to the abundant serum albumin, which in turn extends the effect and reduces the risk of hypoglycemia. Both protracted analogues need to be taken only once daily, and are used for type 1 diabetics as the basal insulin. A combination of a rapid acting and a protracted insulin is also available, making it more likely for patients to achieve an insulin profile that mimics that of the body´s own insulin release.
Insulin is usually taken as subcutaneous injections by single-use syringes with needles, via an insulin pump, or by repeated-use insulin pens with disposable needles. Inhaled insulin is also available in U.S. market now.
Unlike many medicines, insulin currently cannot be taken orally because, like nearly all other proteins introduced into the gastrointestinal tract, it is reduced to fragments (even single amino acid components), whereupon all activity is lost. There has been some research into ways to protect insulin from the digestive tract, so that it can be administered orally or sublingually. While experimental, several companies now have various formulations in human clinical trials, and one, the India-based Biocon, has formed an agreement with BMS to produce an oral-insulin alternative.
In 2015 it was reported that the cone snails Conus geographus and Conus tulipa, venomous sea snails that hunt small fish, use modified forms of insulin in their venom cocktails. The insulin toxin, closer in structure to fishes' than to snails' native insulin, slows down the prey fishes by lowering their blood glucose levels.
In 1869, while studying the structure of the pancreas under a microscope, Paul Langerhans, a medical student in Berlin, identified some previously unnoticed tissue clumps scattered throughout the bulk of the pancreas. The function of the "little heaps of cells", later known as the islets of Langerhans, initially remained unknown, but Edouard Laguesse later suggested they might produce secretions that play a regulatory role in digestion. Paul Langerhans' son, Archibald, also helped to understand this regulatory role. The term "insulin" originates from insula, the Latin word for islet/island.
In 1889, the Polish-German physician Oskar Minkowski, in collaboration with Joseph von Mering, removed the pancreas from a healthy dog to test its assumed role in digestion. Several days after the removal of the dog's pancreas, Minkowski's animal-keeper noticed a swarm of flies feeding on the dog's urine. On testing the urine, they found sugar, establishing for the first time a relationship between the pancreas and diabetes. In 1901 Eugene Lindsay Opie took another major step forward when he clearly established the link between the islets of Langerhans and diabetes: "Diabetes mellitus . . . is caused by destruction of the islets of Langerhans and occurs only when these bodies are in part or wholly destroyed". Before Opie's work, medical science had clearly established the link between the pancreas and diabetes, but not the specific role of the islets.
Over the next two decades researchers made several attempts to isolate - as a potential treatment - whatever the islets produced. In 1906 George Ludwig Zuelzer achieved partial success in treating dogs with pancreatic extract, but he was unable to continue his work. Between 1911 and 1912, E.L. Scott at the University of Chicago used aqueous pancreatic extracts, and noted "a slight diminution of glycosuria", but was unable to convince his director of his work's value; it was shut down. Israel Kleiner demonstrated similar effects at Rockefeller University in 1915, but World War I interrupted his work and he did not return to it.
In 1916 Nicolae Paulescu, a Romanian professor of physiology at the University of Medicine and Pharmacy in Bucharest, developed an aqueous pancreatic extract which, when injected into a diabetic dog, had a normalizing effect on blood-sugar levels. He had to interrupt his experiments because of World War I, and in 1921 he wrote four papers about his work carried out in Bucharest and his tests on a diabetic dog. Later that year, he published "Research on the Role of the Pancreas in Food Assimilation".
Extraction and purification
In October 1920, Canadian Frederick Banting concluded that it was the very digestive secretions that Minkowski had originally studied that were breaking down the islet secretion(s), thereby making it impossible to extract successfully. He jotted a note to himself: "Ligate pancreatic ducts of the dog. Keep dogs alive till acini degenerate leaving islets. Try to isolate internal secretion of these and relieve glycosurea."
The idea was the pancreas's internal secretion, which, it was supposed, regulates sugar in the bloodstream, might hold the key to the treatment of diabetes. A surgeon by training, Banting knew certain arteries could be tied off that would lead to atrophy of most of the pancreas, while leaving the islets of Langerhans intact. He theorized a relatively pure extract could be made from the islets once most of the rest of the pancreas was gone.
In the spring of 1921, Banting traveled to Toronto to explain his idea to J.J.R. Macleod, who was Professor of Physiology at the University of Toronto, and asked Macleod if he could use his lab space to test the idea. Macleod was initially skeptical, but eventually agreed to let Banting use his lab space while he was on holiday for the summer. He also supplied Banting with ten dogs on which to experiment, and two medical students, Charles Best and Clark Noble, to use as lab assistants, before leaving for Scotland. Since Banting required only one lab assistant, Best and Noble flipped a coin to see which would assist Banting for the first half of the summer. Best won the coin toss, and took the first shift as Banting's assistant. Loss of the coin toss may have proved unfortunate for Noble, given that Banting decided to keep Best for the entire summer, and eventually shared half his Nobel Prize money and a large part of the credit for the discovery of insulin with the winner of the toss. Had Noble won the toss, his career might have taken a different path. Banting's method was to tie a ligature around the pancreatic duct; when examined several weeks later, the pancreatic digestive cells had died and been absorbed by the immune system, leaving thousands of islets. They then isolated an extract from these islets, producing what they called "isletin" (what we now know as insulin), and tested this extract on the dogs starting July 27. Banting and Best were then able to keep a pancreatectomized dog named Marjorie alive for the rest of the summer by injecting her with the crude extract they had prepared. Removal of the pancreas in test animals in essence mimics diabetes, leading to elevated blood glucose levels. Marjorie was able to remain alive because the extracts, containing isletin, were able to lower her blood glucose levels.
Banting and Best presented their results to Macleod on his return to Toronto in the fall of 1921, but Macleod pointed out flaws with the experimental design, and suggested the experiments be repeated with more dogs and better equipment. He then supplied Banting and Best with a better laboratory, and began paying Banting a salary from his research grants. Several weeks later, the second round of experiments was also a success; and Macleod helped publish their results privately in Toronto that November. However, they needed six weeks to extract the isletin, which forced considerable delays. Banting suggested they try to use fetal calf pancreas, which had not yet developed digestive glands; he was relieved to find this method worked well. With the supply problem solved, the next major effort was to purify the extract. In December 1921, Macleod invited the biochemist James Collip to help with this task, and, within a month, the team felt ready for a clinical test.
On January 11, 1922, Leonard Thompson, a 14-year-old diabetic who lay dying at the Toronto General Hospital, was given the first injection of insulin. However, the extract was so impure, Thompson suffered a severe allergic reaction, and further injections were canceled. Over the next 12 days, Collip worked day and night to improve the ox-pancreas extract, and a second dose was injected on January 23. This was completely successful, not only in having no obvious side-effects but also in completely eliminating the glycosuria sign of diabetes. The first American patient was Elizabeth Hughes Gossett, the daughter of the governor of New York. The first patient treated in the U.S. was future woodcut artist James D. Havens; Dr. John Ralston Williams imported insulin from Toronto to Rochester, New York, to treat Havens.
Children dying from diabetic ketoacidosis were kept in large wards, often with 50 or more patients in a ward, mostly comatose. Grieving family members were often in attendance, awaiting the (until then, inevitable) death.
In one of medicine's more dramatic moments, Banting, Best, and Collip went from bed to bed, injecting an entire ward with the new purified extract. Before they had reached the last dying child, the first few were awakening from their coma, to the joyous exclamations of their families.
Banting and Best never worked well with Collip, regarding him as something of an interloper, and Collip left the project soon after.
Over the spring of 1922, Best managed to improve his techniques to the point where large quantities of insulin could be extracted on demand, but the preparation remained impure. The drug firm Eli Lilly and Company had offered assistance not long after the first publications in 1921, and they took Lilly up on the offer in April. In November, Lilly made a major breakthrough and was able to produce large quantities of highly refined insulin. Insulin was offered for sale shortly thereafter.
Purified animal-sourced insulin was the only type of insulin available to diabetics until genetic advances occurred later with medical research. The amino acid structure of insulin was characterized in the early 1950s by Frederick Sanger, and the first synthetic insulin was produced simultaneously in the labs of Panayotis Katsoyannis at the University of Pittsburgh and Helmut Zahn at RWTH Aachen University in the early 1960s.
The first genetically engineered, synthetic "human" insulin was produced using E. coli in 1978 by Arthur Riggs and Keiichi Itakura at the Beckman Research Institute of the City of Hope in collaboration with Herbert Boyer at Genentech. Genentech, founded by Swanson, Boyer and Eli Lilly and Company, went on in 1982 to sell the first commercially available biosynthetic human insulin under the brand name Humulin. The vast majority of insulin currently used worldwide is now biosynthetic recombinant "human" insulin or its analogues.
Recombinant insulin is produced either in yeast (usually Saccharomyces cerevisiae) or E. coli. In yeast, insulin may be engineered as a single-chain protein with a KexII endoprotease (a yeast homolog of PCI/PCII) site that separates the insulin A chain from a c-terminally truncated insulin B chain. A chemically synthesized c-terminal tail is then grafted onto insulin by reverse proteolysis using the inexpensive protease trypsin; typically the lysine on the c-terminal tail is protected with a chemical protecting group to prevent proteolysis. The ease of modular synthesis and the relative safety of modifications in that region accounts for common insulin analogs with c-terminal modifications (e.g. lispro, aspart, glulisine). The Genentech synthesis and completely chemical synthesis such as that by Bruce Merrifield are not preferred because the efficiency of recombining the two insulin chains is low, primarily due to competition with the precipitation of insulin B chain.
The Nobel Prize committee in 1923 credited the practical extraction of insulin to a team at the University of Toronto and awarded the Nobel Prize to two men: Frederick Banting and J.J.R. Macleod. They were awarded the Nobel Prize in Physiology or Medicine in 1923 for the discovery of insulin. Banting, insulted that Best was not mentioned, shared his prize with him, and Macleod immediately shared his with James Collip. The patent for insulin was sold to the University of Toronto for one half-dollar.
The primary structure of insulin was determined by British molecular biologist Frederick Sanger. It was the first protein to have its sequence be determined. He was awarded the 1958 Nobel Prize in Chemistry for this work.
In 1969, after decades of work, Dorothy Hodgkin determined the spatial conformation of the molecule, the so-called tertiary structure, by means of X-ray diffraction studies. She had been awarded a Nobel Prize in Chemistry in 1964 for the development of crystallography.
George Minot, co-recipient of the 1934 Nobel Prize for the development of the first effective treatment for pernicious anemia, had diabetes mellitus. Dr. William Castle observed that the 1921 discovery of insulin, arriving in time to keep Minot alive, was therefore also responsible for the discovery of a cure for pernicious anemia.
Nobel Prize controversy
The work published by Banting, Best, Collip and Macleod represented the preparation of purified insulin extract suitable for use on human patients. Although Paulescu discovered the principles of the treatment his saline extract could not be used on humans, and he was not mentioned in the 1923 Nobel Prize. Professor Ian Murray was particularly active in working to correct "the historical wrong" against Nicolae Paulescu. Murray was a professor of physiology at the Anderson College of Medicine in Glasgow, Scotland, the head of the department of Metabolic Diseases at a leading Glasgow hospital, vice-president of the British Association of Diabetes, and a founding member of the International Diabetes Federation. Murray wrote:
Insufficient recognition has been given to Paulescu, the distinguished Romanian scientist, who at the time when the Toronto team were commencing their research had already succeeded in extracting the antidiabetic hormone of the pancreas and proving its efficacy in reducing the hyperglycaemia in diabetic dogs.
- Insulin analog
- Anatomy and physiolology
- Forms of diabetes mellitus
- Other medical / diagnostic uses
- Sonksen P, Sonksen J (2000). "Insulin: understanding its action in health and disease". Br J Anaesth 85 (1): 69–79. PMID 10927996. doi:10.1093/bja/85.1.69.
- American Society of Health-System Pharmacists (2009-02-01). "Insulin Injection". PubMed Health. National Center for Biotechnology Information, U.S. National Library of Medicine. Retrieved 2012-10-12.
- de Souza AM, López JA (2004). "Insulin or insulin-like studies on unicellular organisms: a review.". Braz. arch. biol. technol. 47 (6). doi:10.1590/S1516-89132004000600017.
- LeRoith D, Shiloach J, Heffron R, Rubinovitz C, Tanenbaum R, Roth J (1985). "Insulin-related material in microbes: similarities and differences from mammalian insulins". Can. J. Biochem. Cell Biol. 63 (8): 839–49. PMID 3933801. doi:10.1139/o85-106.
- "Entrez Gene: INS insulin".
- Bell GI, Pictet RL, Rutter WJ, Cordell B, Tischer E, Goodman HM (March 1980). "Sequence of the human insulin gene". Nature 284 (5751): 26–32. PMID 6243748. doi:10.1038/284026a0.
- Melloul D, Marshak S, Cerasi E (2002). "Regulation of insulin gene transcription". Diabetologia 45 (3): 309–26. PMID 11914736. doi:10.1007/s00125-001-0728-y.
- Jang WG, Kim EJ, Park KG, Park YB, Choi HS, Kim HJ et al. (2007). "Glucocorticoid receptor mediated repression of human insulin gene expression is regulated by PGC-1alpha". Biochem. Biophys. Res. Commun. 352 (3): 716–21. PMID 17150186. doi:10.1016/j.bbrc.2006.11.074.
- Sanger F, Tuppy H (September 1951). "The amino-acid sequence in the phenylalanyl chain of insulin. I. The identification of lower peptides from partial hydrolysates". Biochem. J. 49 (4): 463–81. PMC 1197535. PMID 14886310.; Sanger F, Tuppy H (September 1951). "The amino-acid sequence in the phenylalanyl chain of insulin. 2. The investigation of peptides from enzymic hydrolysates". Biochem. J. 49 (4): 481–90. PMC 1197536. PMID 14886311.; Sanger F, Thompson EO (February 1953). "The amino-acid sequence in the glycyl chain of insulin. I. The identification of lower peptides from partial hydrolysates". Biochem. J. 53 (3): 353–66. PMC 1198157. PMID 13032078.; Sanger F, Thompson EO (February 1953). "The amino-acid sequence in the glycyl chain of insulin. II. The investigation of peptides from enzymic hydrolysates". Biochem. J. 53 (3): 366–74. PMC 1198158. PMID 13032079.
- Katsoyannis PG, Fukuda K, Tometsko A, Suzuki K, Tilak M (1964). "Insulin Peptides. X. The Synthesis of the B-Chain of Insulin and Its Combination with Natural or Synthetis A-Chin to Generate Insulin Activity". Journal of the American Chemical Society 86 (5): 930–932. doi:10.1021/ja01059a043.
- Kung YT, Du YC, Huang WT, Chen CC, Ke LT (November 1965). "Total synthesis of crystalline bovine insulin". Sci. Sin. 14 (11): 1710–6. PMID 5881570.
- Marglin A, Merrifield RB (1966). "The synthesis of bovine insulin by the solid phase method". J. Am. Chem. Soc. 88 (21): 5051–2. PMID 5978833. doi:10.1021/ja00973a068.
- Blundell TL, Cutfield JF, Cutfield SM, Dodson EJ, Dodson GG, Hodgkin DC et al. (1971). "Atomic positions in rhombohedral 2-zinc insulin crystals". Nature 231 (5304): 506–11. PMID 4932997. doi:10.1038/231506a0.
- Dunn MF (August 2005). "Zinc-ligand interactions modulate assembly and stability of the insulin hexamer -- a review". Biometals 18 (4): 295–303. PMID 16158220. doi:10.1007/s10534-005-3685-y.
- Ivanova MI, Sievers SA, Sawaya MR, Wall JS, Eisenberg D (November 2009). "Molecular basis for insulin fibril assembly". Proc. Natl. Acad. Sci. U.S.A. 106 (45): 18990–5. PMC 2776439. PMID 19864624. doi:10.1073/pnas.0910080106.
- Rhoades, Rodney A.; Bell, David R. (2009). Medical physiology : principles for clinical medicine (3rd ed. ed.). Philadelphia: Lippincott Williams & Wilkins. pp. 644–647. ISBN 978-0-7817-6852-8.
- C. Ronald Kahn et al. (2005). Joslin's Diabetes Mellitus (14th ed.). Lippincott Williams & Wilkins. ISBN 978-8493531836.
- Steiner DF, Oyer PE (February 1967). "The biosynthesis of insulin and a probable precursor of insulin by a human islet cell adenoma". Proc. Natl. Acad. Sci. U.S.A. 57 (2): 473–80. PMC 335530. PMID 16591494. doi:10.1073/pnas.57.2.473.
- Thomas E Creighton (1993). Proteins: Structures and Molecular Properties (2nd ed.). W H Freeman and Company. pp. 81–83. ISBN 0-7167-2317-4.
- Najjar S (2001). "Insulin Action: Molecular Basis of Diabetes". Encyclopedia of Life Sciences (John Wiley & Sons). ISBN 0470016175. doi:10.1038/npg.els.0001402.
- de la Monte SM, Wands JR (February 2005). "Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease". J. Alzheimers Dis. 7 (1): 45–61. PMID 15750214.
- Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R et al. (February 2005). "Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes?". J. Alzheimers Dis. 7 (1): 63–80. PMID 15750215.
- Cawston EE, Miller LJ (March 2010). "Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor". Br. J. Pharmacol. 159 (5): 1009–21. PMC 2839260. PMID 19922535. doi:10.1111/j.1476-5381.2009.00489.x.
- Nakaki T, Nakadate T, Kato R (August 1980). "Alpha 2-adrenoceptors modulating insulin release from isolated pancreatic islets". Naunyn Schmiedebergs Arch. Pharmacol. 313 (2): 151–3. PMID 6252481. doi:10.1007/BF00498572.
- Layden BT, Durai V, Lowe WL J (2010). "G-Protein-Coupled Receptors, Pancreatic Islets, and Diabetes". Nature Education 3 (9): 13.
- Sircar S (2007). Medical Physiology. Stuttgart: Thieme Publishing Group. pp. 537–538. ISBN 3-13-144061-9.
- Hellman B, Gylfe E, Grapengiesser E, Dansk H, Salehi A (2007). "[Insulin oscillations--clinically important rhythm. Antidiabetics should increase the pulsative component of the insulin release]". Lakartidningen (in Swedish) 104 (32-33): 2236–9. PMID 17822201.
- A Dictionary of Units of Measurement By Russ Rowlett, the University of North Carolina at Chapel Hill. June 13, 2001
- Iwase H, Kobayashi M, Nakajima M, Takatori T (January 2001). "The ratio of insulin to C-peptide can be used to make a forensic diagnosis of exogenous insulin overdosage". Forensic Sci. Int. 115 (1-2): 123–7. PMID 11056282. doi:10.1016/S0379-0738(00)00298-X.
- Fang X, Yu SX, Lu Y, Bast RC, Woodgett JR, Mills GB (October 2000). "Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A". Proc. Natl. Acad. Sci. U.S.A. 97 (22): 11960–5. PMC 17277. PMID 11035810. doi:10.1073/pnas.220413597.
- McManus EJ, Sakamoto K, Armit LJ, Ronaldson L, Shpiro N, Marquez R et al. (April 2005). "Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis". EMBO J. 24 (8): 1571–83. PMC 1142569. PMID 15791206. doi:10.1038/sj.emboj.7600633.
- Menting JG, Whittaker J, Margetts MB, Whittaker LJ, Kong GK, Smith BJ et al. (2013). "How insulin engages its primary binding site on the insulin receptor". Nature 493 (7431): 241–5. PMC 3793637. PMID 23302862. doi:10.1038/nature11781. Lay summary – Australian Broadcasting Commission.
- Dimitriadis G, Mitrou P, Lambadiari V, Maratou E, Raptis SA (August 2011). "Insulin effects in muscle and adipose tissue". Diabetes Res. Clin. Pract. 93 Suppl 1: S52–9. PMID 21864752. doi:10.1016/S0168-8227(11)70014-6.
- Bergamini E, Cavallini G, Donati A, Gori Z (October 2007). "The role of autophagy in aging: its essential part in the anti-aging mechanism of caloric restriction". Ann. N. Y. Acad. Sci. 1114: 69–78. PMID 17934054. doi:10.1196/annals.1396.020.
- Benziane B, Chibalin AV (2008). "Frontiers: skeletal muscle sodium pump regulation: a translocation paradigm". Am. J. Physiol. Endocrinol. Metab. 295 (3): E553–8. PMID 18430962. doi:10.1152/ajpendo.90261.2008.
- Clausen T (2008). "Regulatory role of translocation of Na+-K+ pumps in skeletal muscle: hypothesis or reality?". Am. J. Physiol. Endocrinol. Metab. 295 (3): E727–8; author reply 729. PMID 18775888. doi:10.1152/ajpendo.90494.2008.
- Gupta AK, Clark RV, Kirchner KA (1992). "Effects of insulin on renal sodium excretion". Hypertension 19 (1 Suppl): I78–82. PMID 1730458. doi:10.1161/01.HYP.19.1_Suppl.I78.
- Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J et al. (November 2004). "Intranasal insulin improves memory in humans". Psychoneuroendocrinology 29 (10): 1326–34. PMID 15288712. doi:10.1016/j.psyneuen.2004.04.003.
- Benedict C, Brede S, Schiöth HB, Lehnert H, Schultes B, Born J et al. (2011). "Intranasal insulin enhances postprandial thermogenesis and lowers postprandial serum insulin levels in healthy men". Diabetes 60 (1): 114–8. PMC 3012162. PMID 20876713. doi:10.2337/db10-0329 [Epub'd ahead of print]
- Comninos AN, Jayasena CN, Dhillo WS (2014). "The relationship between gut and adipose hormones, and reproduction". Hum. Reprod. Update 20 (2): 153–74. PMID 24173881. doi:10.1093/humupd/dmt033.
- Duckworth WC, Bennett RG, Hamel FG (October 1998). "Insulin degradation: progress and potential". Endocr. Rev. 19 (5): 608–24. PMID 9793760. doi:10.1210/er.19.5.608.
- Palmer BF, Henrich WL. "Carbohydrate and insulin metabolism in chronic kidney disease". UpToDate, Inc.
- Drug Information Portal NLM – Insulin human USAN http://druginfo.nlm.nih.gov/drugportal/
- From SemBiosys, A New Kind Of Insulin INSIDE WALL STREET By Gene G. Marcial(AUGUST 13, 2007)
- "GM Safflower with Human Pro-Insulin". I-sis.org.uk. Retrieved 2012-07-27.
- Insulin analog
- NDTV Profit – November 16, 2012 – Biocon in pact with Bristol-Myers for oral insulin. Retrieved 2013-04-22.
- "Deadly sea snail uses weaponised insulin to make its prey sluggish". The Guardian. 19 January 2015.
- Safavi-Hemami H, Gajewiak J, Karanth S, Robinson SD, Ueberheide B, Douglass AD et al. (2015). "Specialized insulin is used for chemical warfare by fish-hunting cone snails". Proc. Natl. Acad. Sci. U.S.A. 112 (6): 1743–8. PMID 25605914. doi:10.1073/pnas.1423857112.
- The American Institute of Nutrition (1967). "Proceedings of the Thirty-first Annual Meeting of the American Institute of Nutrition" (PDF). Journal of Nutrition 92: 509.
- Paulesco NC (August 31, 1921). "Recherche sur le rôle du pancréas dans l'assimilation nutritive". Archives Internationales de Physiologie 17: 85–103.
- Lestradet H (1997). "Le 75e anniversaire de la découverte de l'insuline". Diabetes & Metabolism 23 (1): 112.
- Wright JR (December 2002). "Almost famous: E. Clark Noble, the common thread in the discovery of insulin and vinblastine". CMAJ 167 (12): 1391–6. PMC 137361. PMID 12473641.
- Krishnamurthy K (2002). Pioneers in scientific discoveries. Mittal Publications. p. 266. ISBN 978-81-7099-844-0. Retrieved 26 July 2011.
- Bliss M (July 1993). "Rewriting medical history: Charles Best and the Banting and Best myth" (PDF). J Hist Med Allied Sci 48 (3): 253–74. PMID 8409364. doi:10.1093/jhmas/48.3.253.
- Zuger A (October 4, 2010). "Rediscovering the First Miracle Drug". New York Times. Retrieved 2010-10-06.
Elizabeth Hughes was a cheerful, pretty little girl, five feet tall, with straight brown hair and a consuming interest in birds. On Dr. Allen’s diet her weight fell to 65 pounds, then 52 pounds, and then, after an episode of diarrhea that almost killed her in the spring of 1922, 45 pounds. By then she had survived three years, far longer than expected. And then her mother heard the news: Insulin had finally been isolated in Canada.
- Marcotte B (November 22, 2010). "Rochester's John Williams a man of scientific talents". Democrat and Chronicle (Rochester, New York). Gannett Company. pp. 1B, 4B. Archived from the original on November 22, 2010. Retrieved November 22, 2010.
- "Discovery of Insulin". Medical News Today. MediLexicon International Ltd.
- Stretton AO (October 2002). "The first sequence. Fred Sanger and insulin". Genetics 162 (2): 527–32. PMC 1462286. PMID 12399368.
- Costin GE (1964-05-08). "What is the advantage of having melanin in parts of the central nervous system (e.g. substantia nigra)?". IUBMB Life (Time, Inc.) 56 (1): 47–9. PMID 14992380. doi:10.1080/15216540310001659029. Check date values in:
|year= / |date= mismatch(help)
- Wollmer A, Dieken ML, Federwisch M, De Meyts P (2002). Insulin & related proteins structure to function and pharmacology. Boston: Kluwer Academic Publishers. ISBN 1-4020-0655-1.
- "First Successful Laboratory Production of Human Insulin Announced". News Release. Genentech. 1978-09-06. Retrieved 2009-11-03.
- Tof I (1994). "Recombinant DNA technology in the synthesis of human insulin". Little Tree Publishing. Retrieved 2009-11-03.
- Aggarwal SR (December 2012). "What's fueling the biotech engine-2011 to 2012". Nat. Biotechnol. 30 (12): 1191–7. PMID 23222785. doi:10.1038/nbt.2437.
- Kjeldsen T (2000). "Yeast secretory expression of insulin precursors" (PDF). Appl. Microbiol. Biotechnol. 54 (3): 277–86. PMID 11030562. doi:10.1007/s002530000402.
- "The Nobel Prize in Physiology or Medicine 1923". The Nobel Foundation.
- Castle WB (1962). "The Gordon Wilson Lecture. A Century of Curiosity About Pernicious Anemia". Trans. Am. Clin. Climatol. Assoc. 73: 54–80. PMC 2249021. PMID 21408623.
- Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA (March 1922). "Pancreatic Extracts in the Treatment of Diabetes Mellitus". Can Med Assoc J 12 (3): 141–6. PMC 1524425. PMID 20314060.
- Drury MI (July 1972). "The golden jubile of insulin". J Ir Med Assoc 65 (14): 355–63. PMID 4560502.
- Murray I (April 1971). "Paulesco and the isolation of insulin". J Hist Med Allied Sci 26 (2): 150–7. PMID 4930788. doi:10.1093/jhmas/XXVI.2.150.
- Reaven, Gerald M.; Ami Laws (ed.) (1999-04-15). Insulin Resistance: The Metabolic Syndrome X (1st ed.). Totowa, New Jersey: Humana Press. ISBN 0-89603-588-3. doi:10.1226/0896035883.
- Leahy, Jack L.; William T. Cefalu (ed.) (2002-03-22). Insulin Therapy (1st ed.). New York: Marcel Dekker. ISBN 0-8247-0711-7.
- Kumar, Sudhesh; Stephen O'Rahilly (ed.) (2005-01-14). Insulin Resistance: Insulin Action and Its Disturbances in Disease. Chichester, England: Wiley. ISBN 0-470-85008-6.
- Ehrlich, Ann; Carol L. Schroeder (2000-06-16). Medical Terminology for Health Professions (4th ed.). Thomson Delmar Learning. ISBN 0-7668-1297-9.
- Draznin, Boris; Derek LeRoith (September 1994). Molecular Biology of Diabetes: Autoimmunity and Genetics; Insulin Synthesis and Secretion. Totowa, New Jersey: Humana Press. ISBN 0-89603-286-8. doi:10.1226/0896032868.
- Famous Canadian Physicians: Sir Frederick Banting at Library and Archives Canada
- McKeage K, Goa KL (2001). "Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus". Drugs 61 (11): 1599–624. PMID 11577797. doi:10.2165/00003495-200161110-00007.
- Insulin: entry from protein databank
- The History of Insulin
- CBC Digital Archives - Banting, Best, Macleod, Collip: Chasing a Cure for Diabetes
- Discovery and Early Development of Insulin, 1920–1925
- Secretion of Insulin and Glucagon
- Insulin signaling pathway
- Animations of insulin's action in the body at AboutKidsHealth.ca